Initially FDA approved in 2017 following progression on another TKI based on its efficacy in the AURA3 trial against EGFR resistance mutation, T790M [237], third-generation TKI osimertinib is now considered a standard-of-care for untreated, advanced NSCLC patients with sensitizing EGFR aberrations based on the FLAURA study [238]. Here, EGFR is linked to non-small cell lung carcinoma.